Is immunity a mechanism contributing to statin-induced diabetes?

References

• Lindgren P, Jönsson B. Cost-effectiveness of statins revisited: lessons learned about the value of innovation. Eur J Health Econ 2012; 13:445-50; PMID:21528389; http://dx.doi.org/10.1007/s10198-011-0315-1
   PubMed Web of Science ®Google Scholar
• Jackevicius CA, Cox JL, Carreon D, Tu JV, Rinfret S, So D, Johansen H, Kalavrouziotis D, Demers V, Humphries K, et al. Long-term trends in use of and expenditures for cardiovascular medications in Canada. CMAJ 2009; 181:E19-28; PMID:19581604; http://dx.doi.org/10.1503/cmaj.081913
   PubMedGoogle Scholar
• Hoeg JM, Brewer HB. 3-Hydroxy-3-methylglutaryl–coenzyme A reductase inhibitors in the treatment of hypercholesterolemia. JAMA 1987; 258:3532-6; PMID:3316727; http://dx.doi.org/10.1001/jama.1987.03400240064025
   PubMed Web of Science ®Google Scholar
• Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci U S A 1983; 80:4124-8; PMID:6575399; http://dx.doi.org/10.1073/pnas.80.13.4124
   PubMed Web of Science ®Google Scholar
• Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006; 6:358-70; PMID:16639429; http://dx.doi.org/10.1038/nri1839
   PubMed Web of Science ®Google Scholar
• Waiczies S, Bendix I, Zipp F. Geranylgeranylation but not GTP-loading of Rho GTPases determines T cell function. Sci Signal 2008; 1:pt3; PMID:18364514; http://dx.doi.org/10.1126/stke.112pt3
   PubMedGoogle Scholar
• Schönbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004; 109:II18-26; PMID:15173059
   PubMed Web of Science ®Google Scholar
• Blank N, Schiller M, Krienke S, Busse F, Schatz B, Ho AD, Kalden JR, Lorenz H-M. Atorvastatin Inhibits T cell activation through 3-hydroxy-3-methylglutaryl coenzyme a reductase without decreasing cholesterol synthesis. J Immunol 2007; 179:3613-21; PMID:17785796; http://dx.doi.org/10.4049/jimmunol.179.6.3613
   PubMedGoogle Scholar
• Montecucco F, Mach F. Update on statin-mediated anti-inflammatory activities in atherosclerosis. Semin Immunopathol 2009; 31:127-42; PMID:19415282; http://dx.doi.org/10.1007/s00281-009-0150-y
   PubMedGoogle Scholar
• Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels. JAMA 2001; 286:64; PMID:11434828; http://dx.doi.org/10.1001/jama.286.1.64
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20-8; PMID:15635109; http://dx.doi.org/10.1056/NEJMoa042378
   PubMed Web of Science ®Google Scholar
• Ridker PM. Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates? Curr Atheroscler Rep 2013; 15:295; PMID:23225175; http://dx.doi.org/10.1007/s11883-012-0295-3
   PubMed Web of Science ®Google Scholar
• Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 2000; 294:1043-6; PMID:10945857
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999; 353:983-4; PMID:10459915; http://dx.doi.org/10.1016/S0140-6736(98)05917-0
   PubMed Web of Science ®Google Scholar
• Kuijk LM, Mandey SH, Schellens I, Waterham HR, Rijkers GT, Coffer PJ, Frenkel J. Statin synergizes with LPS to induce IL-1beta release by THP-1 cells through activation of caspase-1. Mol Immunol 2008; 45:2158-65; PMID:18242710; http://dx.doi.org/10.1016/j.molimm.2007.12.008
   PubMed Web of Science ®Google Scholar
• Lindholm MW, Nilsson J. Simvastatin stimulates macrophage interleukin-1beta secretion through an isoprenylation-dependent mechanism. Vascul Pharmacol 2007; 46:91-6; PMID:16942919; http://dx.doi.org/10.1016/j.vph.2006.07.001
   PubMedGoogle Scholar
• Mandey SHL, Kuijk LM, Frenkel J, Waterham HR. A role for geranylgeranylation in interleukin-1beta secretion. Arthritis Rheum 2006; 54:3690-5; PMID:17075828; http://dx.doi.org/10.1002/art.22194
   PubMed Web of Science ®Google Scholar
• Montero MT, Matilla J, Gomez-Mampaso E, Lasuncion MA. Geranylgeraniol regulates negatively caspase-1 autoprocessing: implication in the Th1 response against Mycobacterium tuberculosis. J Immunol 2004; 173:4936-44; PMID:15470035; http://dx.doi.org/10.4049/jimmunol.173.8.4936
   PubMedGoogle Scholar
• Montero MT, Hernández O, Suárez Y, Matilla J, Ferruelo AJ, Martínez-Botas J, Gómez-Coronado D, Lasunción MA. Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. Atherosclerosis 2000; 153:303-13; PMID:11164419; http://dx.doi.org/10.1016/S0021-9150(00)00417-2
   PubMed Web of Science ®Google Scholar
• Henriksbo BD, Lau TC, Cavallari JF, Denou E, Chi W, Lally JS, Crane JD, Duggan BM, Foley KP, Fullerton MD, et al. Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance. Diabetes 2014; 63:3742-7; PMID:24917577; http://dx.doi.org/10.2337/db13-1398
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJM, Seshasai SRK, McMurray JJ, Freeman DJ, Jukema JW, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375:735-42; PMID:20167359; http://dx.doi.org/10.1016/S0140-6736(09)61965-6
   PubMed Web of Science ®Google Scholar
• Ma T, Tien L, Fang C-L, Liou Y-S, Jong G-P. Statins and new-onset diabetes: a retrospective longitudinal cohort study. Clin Ther 2012; xx:1-7.
   Google Scholar
• Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ 2013; 346:f2610; PMID:23704171
   PubMed Web of Science ®Google Scholar
• Dormuth CR, Filion KB, Paterson JM, James MT, Teare GF, Raymond CB, Rahme E, Tamim H, Lipscombe L. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ 2014; 348:g3244; PMID:24874977; http://dx.doi.org/10.1136/bmj.g3244
   PubMed Web of Science ®Google Scholar
• Cho Y, Choe E, Lee Y-H, Seo JW, Choi Y, Yun Y, Wang HJ, Ahn CW, Cha BS, Lee HC, et al. Risk of diabetes in patients treated with HMG-CoA reductase inhibitors. Metabolism 2014:1-7.
   Google Scholar
• Freeman DJ, Norrie J, Sattar N, Neely RDG, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, et al. Pravastatin and the development of diabetes mellitus: rvidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103:357-62; PMID:11157685; http://dx.doi.org/10.1161/01.CIR.103.3.357
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-207; PMID:18997196; http://dx.doi.org/10.1056/NEJMoa0807646
   PubMed Web of Science ®Google Scholar
• Protection H, Collaborative S. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22; PMID:12114036; http://dx.doi.org/10.1016/S0140-6736(02)09327-3
   PubMedGoogle Scholar
• Swerdlow DI, Sattar N. A dysglycaemic effect of statins in diabetes: relevance to clinical practice? Diabetologia 2014; 57:2433-5; PMID:25335441; http://dx.doi.org/10.1007/s00125-014-3409-3
   PubMedGoogle Scholar
• Goldfine AB. Statins: is it really time to reassess benefits and risks? N Engl J Med 2012; 366:1752-5; PMID:22533536; http://dx.doi.org/10.1056/NEJMp1203020
   PubMed Web of Science ®Google Scholar
• Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 2010; 33:171-87; PMID:20158283; http://dx.doi.org/10.2165/11319380-000000000-00000
   PubMed Web of Science ®Google Scholar
• Reiner Ž. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol 2013; 10:453-64; PMID:23736519; http://dx.doi.org/10.1038/nrcardio.2013.80
   PubMed Web of Science ®Google Scholar
• Pencina MJ, Navar-Boggan AM, D'Agostino RB, Williams K, Neely B, Sniderman AD, Peterson ED. Application of new cholesterol guidelines to a population-based sample. N Engl J Med 2014; 370:1422-31; PMID:24645848; http://dx.doi.org/10.1056/NEJMoa1315665
   PubMed Web of Science ®Google Scholar
• Seshasai SRK, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364:829-41; PMID:21366474; http://dx.doi.org/10.1056/NEJMoa1008862
   PubMed Web of Science ®Google Scholar
• Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JEL, Shah T, Sofat R, Stender S, Johnson PCD, Scott RA, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2014:1-11.
   Google Scholar
• Fullerton MD, Steinberg GR, Schertzer JD. Immunometabolism of AMPK in insulin resistance and atherosclerosis. Mol Cell Endocrinol 2013; 366:224-34; PMID:22361321; http://dx.doi.org/10.1016/j.mce.2012.02.004
   PubMed Web of Science ®Google Scholar
• Schertzer JD, Steinberg GR. Immunometabolism: the interface of immune and metabolic responses in disease. Immunol Cell Biol 2014; 92:303; PMID:24613974; http://dx.doi.org/10.1038/icb.2014.12
   PubMed Web of Science ®Google Scholar
• Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab 2012; 15:635-45; PMID:22560216; http://dx.doi.org/10.1016/j.cmet.2012.04.001
   PubMed Web of Science ®Google Scholar
• Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid–induced insulin resistance. 2006; 116:3015-25; PMID:17053832
   PubMedGoogle Scholar
• Könner AC, Brüning JC. Toll-like receptors: linking inflammation to metabolism. Trends Endocrinol Metab 2011; 22:16-23; PMID:20888253; http://dx.doi.org/10.1016/j.tem.2010.08.007
   PubMed Web of Science ®Google Scholar
• Chi W, Dao D, Lau TC, Henriksbo BD, Cavallari JF, Foley KP, Schertzer JD. Bacterial peptidoglycan stimulates adipocyte lipolysis via NOD1. PLoS One 2014; 9:e97675; PMID:24828250; http://dx.doi.org/10.1371/journal.pone.0097675
   PubMed Web of Science ®Google Scholar
• Schertzer JD, Tamrakar AK, Magalhães JG, Pereira S, Bilan PJ, Fullerton MD, Liu Z, Steinberg GR, Giacca A, Philpott DJ, et al. NOD1 activators link innate immunity to insulin resistance. Diabetes 2011; 60:2206-15; PMID:21715553; http://dx.doi.org/10.2337/db11-0004
   PubMed Web of Science ®Google Scholar
• Tamrakar AK, Schertzer JD, Chiu TT, Foley KP, Bilan PJ, Philpott DJ, Klip A. NOD2 activation induces muscle cell-autonomous innate immune responses and insulin resistance. Endocrinology 2010; 151:5624-37; PMID:20926588; http://dx.doi.org/10.1210/en.2010-0437
   PubMed Web of Science ®Google Scholar
• Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010; 11:136-40; PMID:20023662; http://dx.doi.org/10.1038/ni.1831
   PubMed Web of Science ®Google Scholar
• Youm Y-H, Adijiang A, Vandanmagsar B, Burk D, Ravussin A, Dixit VD. Elimination of the NLRP3-ASC inflammasome protects against chronic obesity-induced pancreatic damage. Endocrinology 2011; 152:4039-45; PMID:21862613; http://dx.doi.org/10.1210/en.2011-1326
   PubMed Web of Science ®Google Scholar
• Lee H-M, Kim J-J, Kim HJ, Shong M, Ku BJ, Jo E-K. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 2013; 62:194-204; PMID:23086037; http://dx.doi.org/10.2337/db12-0420
   PubMed Web of Science ®Google Scholar
• Vandanmagsar B, Youm Y-H, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM, Dixit VD. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17:179-88; PMID:21217695; http://dx.doi.org/10.1038/nm.2279
   PubMed Web of Science ®Google Scholar
• Stienstra R, Joosten LAB, Koenen T, van Tits B, van Diepen JA, van den Berg SAA, Rensen PCN, Voshol PJ, Fantuzzi G, Hijmans A, et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab 2010; 12:593-605; PMID:21109192; http://dx.doi.org/10.1016/j.cmet.2010.11.011
   PubMed Web of Science ®Google Scholar
• Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science 2010; 327:296-300; PMID:20075245; http://dx.doi.org/10.1126/science.1184003
   PubMed Web of Science ®Google Scholar
• Grant RW, Dixit VD. Mechanisms of disease: inflammasome activation and the development of type 2 diabetes. Front Immunol 2013; 4:50; PMID:23483669; http://dx.doi.org/10.3389/fimmu.2013.00050
   PubMed Web of Science ®Google Scholar
• Haneklaus M, O'Neill LA, Coll RC. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. Curr Opin Immunol 2013:2-7.
   Google Scholar
• Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D, Fernandes-Alnemri T, Wu J, Monks BG, Fitzgerald KA, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 2009; 183:787-91; PMID:19570822; http://dx.doi.org/10.4049/jimmunol.0901363
   PubMed Web of Science ®Google Scholar
• Kono H, Kimura Y, Latz E. Inflammasome activation in response to dead cells and their metabolites. Curr Opin Immunol 2014; 30C:91-8; http://dx.doi.org/10.1016/j.coi.2014.09.001
   Web of Science ®Google Scholar
• Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356:1517-26; PMID:17429083; http://dx.doi.org/10.1056/NEJMoa065213
   PubMed Web of Science ®Google Scholar
• Ridker PM. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? Trans Am Clin Climatol Assoc 2013; 124:174-90; PMID:23874021
   PubMedGoogle Scholar
• Liao Y-H, Lin Y-C, Tsao S-T, Lin Y-C, Yang A-J, Huang C-T, Huang K-C, Lin WW. HMG-CoA reductase inhibitors activate caspase-1 in human monocytes depending on ATP release and P2´7 activation. J Leukoc Biol 2012; 92:1-11; PMID:22745457; http://dx.doi.org/10.1189/jlb.0312130
   PubMedGoogle Scholar
• Lamkanfi M, Mueller JL, Vitari AC, Misaghi S, Fedorova A, Deshayes K, Lee WP, Hoffman HM, Dixit VM. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol 2009; 187:61-70; PMID:19805629; http://dx.doi.org/10.1083/jcb.200903124
   PubMed Web of Science ®Google Scholar
• Jager J, Grémeaux T, Cormont M, Le Marchand-Brustel Y, Tanti J-F. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 2007; 148:241-51; PMID:17038556; http://dx.doi.org/10.1210/en.2006-0692
   PubMed Web of Science ®Google Scholar
• Davaro F, Forde SD, Garfield M, Jiang Z, Halmen K, Tamburro ND, Kurt-Jones E, Fitzgerald KA, Golenbock DT, Wang D. 3-Hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (Statin)-induced 28-kDa interleukin-1β interferes with mature IL-1β signaling. J Biol Chem 2014; 289:16214-22; PMID:24790079; http://dx.doi.org/10.1074/jbc.M114.571505
   PubMed Web of Science ®Google Scholar
• Bruun JM, Stallknecht B, Helge JW, Richelsen B. Interleukin-18 in plasma and adipose tissue: effects of obesity, insulin resistance, and weight loss. Eur J Endocrinol 2007; 157:465-71; PMID:17893261; http://dx.doi.org/10.1530/EJE-07-0206
   PubMed Web of Science ®Google Scholar
• Lindegaard B, Matthews VB, Brandt C, Hojman P, Allen TL, Estevez E, Watt MJ, Bruce CR, Mortensen OH, Syberg S, et al. Interleukin-18 activates skeletal muscle AMPK and reduces weight gain and insulin resistance in mice. Diabetes 2013; 62:3064-74; PMID:23670974; http://dx.doi.org/10.2337/db12-1095
   PubMed Web of Science ®Google Scholar
• Lamkanfi M, Kanneganti T-D, Van Damme P, Vanden Berghe T, Vanoverberghe I, Vandekerckhove J, Vandenabeele P, Gevaert K, Núñez G. Targeted peptidecentric proteomics reveals caspase-7 as a substrate of the caspase-1 inflammasomes. Mol Cell Proteomics 2008; 7:2350-63; PMID:18667412; http://dx.doi.org/10.1074/mcp.M800132-MCP200
   PubMed Web of Science ®Google Scholar
• Kahns S, Kalai M, Jakobsen LD, Clark BFC, Vandenabeele P, Jensen PH. Caspase-1 and caspase-8 cleave and inactivate cellular parkin. J Biol Chem 2003; 278:23376-80; PMID:12692130; http://dx.doi.org/10.1074/jbc.M300495200
   PubMedGoogle Scholar
• Shao W, Yeretssian G, Doiron K, Hussain SN, Saleh M. The caspase-1 digestome identifies the glycolysis pathway as a target during infection and septic shock. J Biol Chem 2007; 282:36321-9; PMID:17959595; http://dx.doi.org/10.1074/jbc.M708182200
   PubMed Web of Science ®Google Scholar
• Birnbaum Y, Nanhwan MK, Ling S, Perez-Polo JR, Ye Y, Bajaj M. PTEN upregulation may explain the development of insulin resistance and type 2 diabetes with high dose statins. Cardiovasc Drugs Ther 2014; 28(5):447-57; PMID:25106875
   PubMedGoogle Scholar
• Teresi RE, Planchon SM, Waite KA, Eng C. Regulation of the PTEN promoter by statins and SREBP. Hum Mol Genet 2008; 17:919-28; PMID:18065496; http://dx.doi.org/10.1093/hmg/ddm364
   PubMedGoogle Scholar
• Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006; 7:85-96; PMID:16493415; http://dx.doi.org/10.1038/nrm1837
   PubMed Web of Science ®Google Scholar
• Wagner BK, Kitami T, Gilbert TJ, Peck D, Ramanathan A, Schreiber SL, Golub TR, Mootha VK. Large-scale chemical dissection of mitochondrial function. Nat Biotechnol 2008; 26:343-51; PMID:18297058; http://dx.doi.org/10.1038/nbt1387
   PubMed Web of Science ®Google Scholar
• Wagner BK, Gilbert TJ, Hanai J, Imamura S, Bodycombe NE, Bon RS, Waldmann H, Clemons PA, Sukhatme VP, Mootha VK. A small-molecule screening strategy to identify suppressors of statin myopathy. ACS Chem Biol 2011; 6:900-4; PMID:21732624; http://dx.doi.org/10.1021/cb200206w
   PubMedGoogle Scholar
• Kaufmann P, Török M, Zahno A, Waldhauser KM, Brecht K, Krähenbühl S. Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci 2006; 63:2415-25; PMID:17013560; http://dx.doi.org/10.1007/s00018-006-6235-z
   PubMed Web of Science ®Google Scholar
• Thuc LC, Teshima Y, Takahashi N, Nagano-Torigoe Y, Ezaki K, Yufu K, Nakagawa M, Hara M, Saikawa T. Mitochondrial K(ATP) channels-derived reactive oxygen species activate pro-survival pathway in pravastatin-induced cardioprotection. Apoptosis 2010; 15:669-78; PMID:20151195; http://dx.doi.org/10.1007/s10495-010-0473-0
   PubMedGoogle Scholar
• Sánchez CA, Rodríguez E, Varela E, Zapata E, Páez A, Massó FA, Montaño LF, Lóopez-Marure R. Statin-induced inhibition of MCF-7 breast cancer cell proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated by an enhanced oxidative stress. Cancer Invest 2008; 26:698-707; http://dx.doi.org/10.1080/07357900701874658
   PubMed Web of Science ®Google Scholar
• Muñoz-Planillo R, Kuffa P, Martínez-Colón G, Smith BL, Rajendiran TM, Núñez G. K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 2013; 38:1142-53; http://dx.doi.org/10.1016/j.immuni.2013.05.016
   PubMed Web of Science ®Google Scholar
• Sinensky M. Recent advances in the study of prenylated proteins. Biochim Biophys Acta–Mol Cell Biol Lipids 2000; 1484:93-106; http://dx.doi.org/10.1016/S1388-1981(00)00009-3
   PubMed Web of Science ®Google Scholar
• Stenmark H, Olkkonen VM. Protein family review The Rab GTPase family. 2001:1-7.
   Google Scholar
• Spindler SR, Li R, Dhahbi JM, Yamakawa A, Mote P, Bodmer R, Ocorr K, Williams RT, Wang Y, Ablao KP. Statin treatment increases lifespan and improves cardiac health in Drosophila by decreasing specific protein prenylation. PLoS One 2012; 7:e39581; PMID:22737247; http://dx.doi.org/10.1371/journal.pone.0039581
   PubMed Web of Science ®Google Scholar
• Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R. Changes in gut microbiota control metabolic endotoxemia-induced Inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008; 57:1470-81; PMID:18305141; http://dx.doi.org/10.2337/db07-1403
   PubMed Web of Science ®Google Scholar
• Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56:1761-72; PMID:17456850; http://dx.doi.org/10.2337/db06-1491
   PubMed Web of Science ®Google Scholar
• Steinberg GR, Schertzer JD. AMPK promotes macrophage fatty acid oxidative metabolism to mitigate inflammation: implications for diabetes and cardiovascular disease. Immunol Cell Biol 2014; 92:340-5; PMID:24638063; http://dx.doi.org/10.1038/icb.2014.11
   PubMed Web of Science ®Google Scholar
• Jourdan T, Godlewski G, Cinar R, Bertola A, Szanda G, Liu J, Tam J, Han T, Mukhopadhyay B, Skarulis MC, et al. Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat Med 2013; 19:1132-40; PMID:23955712; http://dx.doi.org/10.1038/nm.3265
   PubMed Web of Science ®Google Scholar
• Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, Becker C, Franchi L, Yoshihara E, Chen Z, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol 2010; 11:897-904; PMID:20835230; http://dx.doi.org/10.1038/ni.1935
   PubMed Web of Science ®Google Scholar
• Mitchell P, Marette A. Statin-induced insulin resistance through inflammasome activation: sailing between scylla and charybdis. Diabetes 2014; 63:3569-71; PMID:25342725; http://dx.doi.org/10.2337/db14-1059
   PubMed Web of Science ®Google Scholar